news
Our CEO and CMO, Steffen Hovard and Dr. Steven Siegel will be heading to Washington D.C. for this year’s American Urogynecologic Society PFD Week and are looking forward to connecting with old friends and meeting new ones. Reach out via LinkedIn or email to meet up. Hope to see you there! LinkedIn X
Did you know that this week is Urology Week 2024? To commemorate the occasion, MassDevice published an article on the top 10 urology device stories of 2024 so far and it featured our Series D round! LinkedIn X
The seasoned life sciences executive will play a key role as the company completes the regulatory process and prepares for commercialization of its Neuspera SNM System SAN JOSE, Calif., Sept. 12, 2024 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Sacral Neuromodulation (SNM) System, announced today that Bunty Banerjee has joined the company as its first Chief Operating […]
We’re excited to welcome two new members to our Neuspera team: Douglas Sullivan as Supply Chain Director and Jeff Siegel, CPA as Controller. We are grateful to have their expertise on the team as we continue working to improve sacral neuromodulation options for treating OAB!
Neuspera Medical is very excited and grateful for the tremendous interest in our progress towards reinventing sacral neuromodulation for treating OAB. The Neuspera Sacral Neuromodulation System includes innovations designed to significantly impact patient acceptance and satisfaction with this potentially life-changing therapy in a large market that has been largely underserved to date. Our two recent […]
Capital from Olympus Innovation Ventures, another strategic investor and several institutional investors will fund through expected PMA approval SAN JOSE, Calif., July 15, 2024 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, announced the closing of its Series D funding round raising $23 million and led by Vertex Ventures HC and Treo […]
Check out this “stimulating” deep-dive conversation into how our respective technologies are shifting the paradigm for how patients with underlying neurological conditions may receive care in the not-too-distant future. LinkedIn X
65 Startups Named to MedTech Innovator 2024 Cohort
The American Urological Association (AUA) and Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) recently published their 2024 Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder (OAB). The guideline promotes a shared decision-making process between the patient and physician that weighs the patient’s comorbidities along with expressed values, preferences, and treatment […]
The international study is evaluating the safety and efficacy of the Neuspera System for the treatment of urinary urge incontinence (UUI), a symptom of overactive bladder (OAB) SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ — Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, today announced it has completed patient enrollment and implant procedures […]